440 related articles for article (PubMed ID: 25807854)
1. Bortezomib in ABO-incompatible kidney transplant desensitization: a case report.
Wong NL; O'Connell P; Chapman JR; Nankivell B; Kable K; Webster AC; Wong G
Nephrology (Carlton); 2015 Mar; 20 Suppl 1():22-4. PubMed ID: 25807854
[TBL] [Abstract][Full Text] [Related]
2. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
Yuan XP; Wang CX; Gao W; Fu Q; He XS
Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
[TBL] [Abstract][Full Text] [Related]
3. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
4. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
7. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience.
Kute VB; Vanikar AV; Trivedi HL; Shah PR; Goplani KR; Patel HV; Gumber MR; Patel RD; Kanodia KV; Suthar KS; Trivedi VB; Modi PR
Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):662-9. PubMed ID: 21743208
[TBL] [Abstract][Full Text] [Related]
8. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.
Opelz G; Morath C; Süsal C; Tran TH; Zeier M; Döhler B
Transplantation; 2015 Feb; 99(2):400-4. PubMed ID: 25050471
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
Han S; Hwang E; Park S; Park U; Kim H; Cho W
Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
[TBL] [Abstract][Full Text] [Related]
10. Living-donor kidney transplant in T-cell and B-cell flow cytometry crossmatch-positive patients.
Terasaka S; Kitada H; Okabe Y; Kawanami S; Noguchi H; Miyamoto K; Tsuchimoto A; Masutani K; Tanaka M
Exp Clin Transplant; 2014 Jun; 12(3):227-32. PubMed ID: 24907723
[TBL] [Abstract][Full Text] [Related]
11. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.
Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M
Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587
[TBL] [Abstract][Full Text] [Related]
12. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
[TBL] [Abstract][Full Text] [Related]
13. Desensitization in the Setting of HLA-Incompatible Kidney Transplant.
Malvezzi P; Jouve T; Noble J; Rostaing L
Exp Clin Transplant; 2018 Aug; 16(4):367-375. PubMed ID: 29863455
[TBL] [Abstract][Full Text] [Related]
14. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
15. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
Becker LE; Siebert D; Süsal C; Opelz G; Leo A; Waldherr R; Macher-Goeppinger S; Schemmer P; Schaefer SM; Klein K; Beimler J; Zeier M; Schwenger V; Morath C
Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
[TBL] [Abstract][Full Text] [Related]
16. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
[TBL] [Abstract][Full Text] [Related]
17. Recent developments in desensitization of crossmatch-positive kidney transplant recipients.
Morath C; Opelz G; Zeier M; Süsal C
Transplant Proc; 2012; 44(6):1648-51. PubMed ID: 22841236
[TBL] [Abstract][Full Text] [Related]
18. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates.
Rostaing L; Maggioni S; Hecht C; Hermelin M; Faudel E; Kamar N; Sallusto F; Doumerc N; Allal A
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():165-9. PubMed ID: 25894148
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Successful Living Donor Kidney Transplantation in a Highly Human Leukocyte Antigen-Sensitized Recipient With a Positive Cytotoxic Crossmatch Using Bortezomib-Based Desensitization Without Intravenous Immunoglobulin.
Revollo JY; Cuffy MC; Abu Jawdeh BG; Paterno F; Girnita A; Brailey P; Alloway RR; Woodle ES
Transplant Proc; 2015 Sep; 47(7):2254-7. PubMed ID: 26361693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
